Elsevier Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Jakubowski
    Jakubowski
  4. Papadopoulos
    Papadopoulos
  5. Castro-Malaspina
    Castro-Malaspina
  6. Tamari
    Tamari
  7. Shaffer
    Shaffer
  8. Dahi
    Dahi
  9. Ponce
    Ponce
  10. Shah
    Shah

Groups

  1. Bone Marrow Transplant (87)
  2. CTCR Scholars (87)
  3. Center for Hematologic Malignancies (87)
  4. Department of Medicine (87)
  5. Hematologic Malignancies, Division of (87)
  6. MSK Grad Students (87)
  7. Master of Science in Clinical and Translational Cancer Research (87)
  8. Survivorship Research (72)
  9. DigITs Research Group (49)
  10. Biostatistics Service (42)
Search Within
  1. "Roni Tamari"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (30)
  3. Review (3)
  4. Book Section (1)
Groups
  1. Bone Marrow Transplant (87)
  2. CTCR Scholars (87)
  3. Center for Hematologic Malignancies (87)
  4. Department of Medicine (87)
  5. Hematologic Malignancies, Division of (87)
  6. MSK Grad Students (87)

More Groups

People
  1. Roni Tamari (87)
  2. Sergio Giralt (72)
  3. Miguel-Angel Perales (58)
  4. Ann Jakubowski (55)
  5. Esperanza Papadopoulos (53)
  6. Molly Maloy (49)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (8)
  5. 2021 (5)
  6. 2020 (12)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (68)
  2. Transplantation and Cellular Therapy (17)
  3. Best Practice and Research: Clinical Haematology (1)
  4. Hematopoietic Cell Transplantation for Malignant Conditions (1)

Results (87)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Letermovir for prevention of recurrent cytomegalovirus in high-risk allogeneic hematopoietic cell transplantation recipients
    Journal Article

    Han, G.; Stern, A.; Lee, Y. J.; Li, Y.; Dahi, P. B.; Tamari, R.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; Shaffer, B.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Donor-derived malignancy and transplantation morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplantation
    Review

    Williams, L. S.; Williams, K. M.; Gillis, N.; Bolton, K.; Damm, F.; Deuitch, N. T.; Farhadfar, N.; Gergis, U.; Keel, S. B.; Michelis, F. V.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines
    Review

    DeFilipp, Z.; Ciurea, S. O.; Cutler, C.; Robin, M.; Warlick, E. D.; Nakamura, R.; Brunner, A. M.; Dholaria, B.; Walker, A. R.; Kröger, N.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Daratumumab salvage therapy for refractory immune cytopenias after ALLOHCT
    Meeting Abstract

    Lin, A.; DeRespiris, L.; Chinapen, S.; Barker, J. N.; Castro-Malaspina, H.; Dahi, P. B.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Lin, R. J.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Prolonged post-transplant ruxolitinib therapy is associated with protection from severe gvhd after allogeneic HCT
    Meeting Abstract

    DeFilipp, Z.; Kim, H. T.; Knight, L.; Kelley, D.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Vasu, S.; Abedin, S.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Humoral response to COVID-19 vaccination given pre-cellular therapy wanes in patients after cellular therapy: An argument for full reimmunization
    Meeting Abstract

    Shah, G. L.; Chung, D. J.; Tamari, R.; Politikos, I.; Jakubowski, A. A.; Marcello, L.; Doddi, S.; Ramanathan, L.; Pessin, M.; Palazzo, M.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • A multi-center collaborative study of outcomes of TP53- mutated MDS/AML patients following allogeneic HCT
    Meeting Abstract

    Byrne, M.; Kurian, T.; Patel, D.; Tamari, R.; Hong, S.; Abdelhakim, H.; Klein, V.; Rojas, P.; Madhavan, R.; Kent, A; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Double unit cord blood transplantation compares favorably to T-cell depleted matched adult donor transplantation for the treatment of acute leukemia due to a robust protection against relapse
    Meeting Abstract

    Politikos, I.; Flynn, J.; Devlin, S. M.; Fingrut, W.; Maloy, M. A.; Naputo, K.; Chinapen, S.; Rodriguez, N. T.; Quach, S.; Dominguez, Y.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation (HCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M.; Gooptu, M.; Bin, C.; Deeg, J.; Gallacher, P.; Wennborg, A.; Kaylor Hickman, D.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save